Work Here?
Overview
Valius Sciences develops precision oncology diagnostics that build detailed molecular profiles of tumors across DNA, RNA, and proteins to guide treatment choices. Its test combines multi-omic data and extensive gene expression analysis to identify actionable targets and cancer drivers that may be missed by standard tests. Rather than static PDFs, it offers a partnership model with an AI-queryable platform that stores all patient data and enables ongoing analysis and collaboration with Valius's scientific team. The goal is to help patients and clinicians prioritize effective therapies and plan for recurrence or progression through continuous, data-driven insights.
About Valius Sciences
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
1-10
Company Stage
Seed
Total Funding
$10M
Headquarters
San Francisco, California
Founded
2025
Get referred to Valius Sciences
See people who can refer or advise you
Simplify's Take
What believers are saying
- Valius raised $13.5 million on April 9, 2026, backing expansion.
- The company regularly finds actionable markers missed by standard diagnostics, strengthening clinical pull.
- Single-cell RNA sequencing and AI-queryable reports deepen differentiation for aggressive, treatment-resistant cancers.
What critics are saying
- Caris launched Detect on July 1, 2026, intensifying precision oncology competition immediately.
- Tempus FDA approval for xT CDx and xF expansion strengthens reimbursement economics in 2026.
- At $50,000-$150,000 per case, Valius faces existential adoption risk if insurers stay absent.
What makes Valius Sciences unique
- Valius combines DNA, RNA, protein, and single-cell analysis across FFPE tissue.
- Its patient platform shares all data, enabling ongoing scientific collaboration and queryable insights.
- Founders Edward Larkin, Claire Oldfield, and Sarah Hesse bring oncology, consulting, and translational depth.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$10M
Above
Industry Average
Funded Over
1 Rounds
Industry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Company Equity
Professional Development Budget
Company News
We're bringing maximalist diagnostics to more patients.
Valius Sciences, a San Francisco-based healthcare diagnostics company focused on cancer treatment, has raised more than $10 million in a Series Seed financing round. The round was led by 8VC and Basis Set Ventures. Sidley represented the company in the transaction.
Valius Sciences is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Valius Sciences
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
1-10
Company Stage
Seed
Total Funding
$10M
Headquarters
San Francisco, California
Founded
2025
Valius Sciences is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today